Exoskeleton Bots track To da moon signal?

Recently, I noticed an interesting trend: the market for medical exoskeleton robots is expected to grow at an annual rate of 32.2% (by 2030), but the stock prices of related companies have plummeted.

Three players worth paying attention to:

**EKSO (Ekso Bionics)** - Established in 2005, this veteran has seen its stock price halve this year, but its first-quarter revenue remains steady at 3.8 million USD, with an EV/EBITDA of only 0.46x, making its valuation absurdly cheap. Recently, it has collaborated with Shepherd Center for research and development, maintaining a stable cash flow.

**LFWD (ReWalk)** - Specializes in rehabilitation training for patients with lower limb paralysis. In the first quarter, although revenue fell short by $250,000, profitability indicators exceeded expectations. The company expects annual revenue to be between 28-32 million, with a 3-year compound growth rate of 53.52%, and an EV/Revenue of only 0.75x.

**MYO (Myomo)** - Focuses on electronic upper limb braces, catering to users such as stroke and cerebral palsy patients with neuromuscular injuries. Revenue of $3.8 million in the first quarter, with a 5-year compound growth rate of 45.86%. Although the PS ratio of 8.11x seems expensive, this is a growth story, not a value stock.

Commonality: Both are in high barrier niche tracks and have been misjudged. However, the early industry inevitably has pitfalls, and you need to do your own homework.